Suchen
Solid Biosciences Inc
SLDBZur Watchlist hinzufügen
8.050USD
-0.440-5.18%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
792.08MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Solid Biosciences Inc Unternehmen
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Solid Biosciences Inc Informationen
BörsenkürzelSLDB
Name des UnternehmensSolid Biosciences Inc
IPO-datumJan 26, 2018
CEOCumbo (Alexander)
Anzahl der mitarbeiter100
WertpapierartOrdinary Share
GeschäftsjahresendeJan 26
Addresse500 Rutherford Avenue
StadtCHARLESTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02129
Telefon16173374680
Websitehttps://www.solidbio.com/
BörsenkürzelSLDB
IPO-datumJan 26, 2018
CEOCumbo (Alexander)
Führungskräfte von Solid Biosciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.41K
+1.22%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
146.16K
+8.65%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
141.59K
+2.43%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
105.08K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
82.81K
-43.95%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
74.32K
-46.95%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
63.78K
-52.65%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.41K
+1.22%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
146.16K
+8.65%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
141.59K
+2.43%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
105.08K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
82.81K
-43.95%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
74.32K
-46.95%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Solid Biosciences Inc?
Die fünf größten Anteilseigner von Solid Biosciences Inc sind: Mr. Alexander (Bo) Cumbo
Wie viele Institutionen halten Anteile an Solid Biosciences Inc (SLDB)?
Mit Stand vom 2026Q1 halten 271 Institutionen Anteile an Solid Biosciences Inc, mit einem Gesamtmarktwert von etwa 83.89M, was 85.25% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -13751546.00 gestiegen.